Pneumococcal vertebral osteomyelitis | Other invasive pneumococcal disease | P-value | |
---|---|---|---|
n = 14 (*) | n = 194 (**) | (*) vs (**) | |
Age (y) (median) | 69 (35–88) | 73 (28–95) | 0.433 |
Female | 5 (35.7%) | 70 (36.1%) | 0.999 |
Body weight (kg) (median) | 52.8 (27.5–80.0) | 49.8 (29.5–92.4) | 0.272 |
ADL impairment (Katz Index) | 0 | 24/179 (13.4%) | 0.325 |
Residents in long-term care facilities | 0 | 15 (7.7%) | 0.605 |
Charlson comorbidity index (median) | 1 (0–6) | 1 (0–9) | 0.461 |
Diabetes mellitus | 5 (35.7%) | 37 (19.1%) | 0.164 |
Malignancy | 2 (14.3%) | 35 (18.0%) | 0.999 |
Dialysis | 0 | 5 (2.6%) | 0.999 |
Splenectomy | 0 | 3 (1.5%) | 0.999 |
Immunosuppressants or chemotherapy | 2 (14.3%) | 29 (14.9%) | 0.999 |
Antibiotics used before culture obtained | 1 (7.1%) | 28 (14.4%) | 0.698 |
Smoking | 6/12 (50.0%) | 98/181 (54.1%) | 0.780 |
Heavy alcohol intake | 4 (28.6%) | 12 (6.2%) | 0.015 |
Seasonality (winter: December-March) | 2 (14.3%) | 97 (50.0%) | 0.011 |
Hospital-onset infections | 0 | 22 (11.3%) | 0.371 |
Clinical Severity Scale | 0.224 | ||
Severe sepsis | 7 (50.0%) | 69 (35.6%) | |
Septic shock | 0 | 31 (16.0%) | |
Initial antimicrobial therapy | 0.292 | ||
Beta-lactam agents monotherapy | 7 (50.0%) | 129/189 (68.3%) | |
Beta-lactam agents combination therapy | 7 (50.0%) | 51/189 (27.0%) | |
Other antibiotics | 0 | 9/189 (4.7%) | |
Duration of antibiotic therapy (days) | 52 (20–330) | 15 (0–105) | 0.035 |
14-day mortality | 0/14 (0%) | 29/188 (15.4%) | 0.228 |
30-day mortality | 0/14 (0%)a | 37/182 (20.3%) | 0.076 |